- Clone
- W20057A (See other available formats)
- Regulatory Status
- RUO
- Other Names
- IFN-alpha 2B, IFN-alphaA, IFNA2, IFNA2B
- Isotype
- Rat IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Quantity Check Availability | Save | ||
---|---|---|---|---|---|---|
638253 | 100 µg | £295 | ||||
638254 | 1 mg | £777 |
Interferons are divided into type I, II, and III. Type I IFNs (IFN-α and IFN-β) are most abundant in number, distribution, and expression. Also, they are highly conserved among mammals in both structure and function. IFN-α2 has been used in the treatment of cancer such as bladder cancer, hepatocellular carcinoma, and leukemia. IFN-α2 augments the suppressed immune functions in patients with head and neck squamous cell carcinoma (HNSCC). IFN-α2 initiated T and NK cell mediated cytotoxicity of tumor cells through IFNγ dependent and independent mechanisms. IFN-α2 enhances suppressed T cell cytotoxicity by stimulation of the perforin-granzyme B system (IFNγ dependent). Also, IFN-α2 induces the expression of perforin-granzyme B in NK cells. In a preliminary study, IFN-α2 appears to demonstrate effective immunostimulatory properties impacting clinical outcomes in tongue squamous cell carcinoma patients. IFN-α has also been used in the treatment of chronic hepatitis C (CHC) despite its relatively instability and need for frequent parenteral administration. Although pegylation reduces IFN-α in vitro activity, polyethylene glycol (PEG)-IFN-α increases the stability and plasma half-life of IFN-α resulting in PEG-IFN-α replacing native IFN-α in CHC treatment.
Product DetailsProduct Details
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Recombinant human IFN-α2
- Formulation
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
- Endotoxin Level
- Less than 0.01 EU/μg of the protein (less than 0.001 ng/μg of the protein) as determined by the LAL test
- Preparation
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- Concentration
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
- Application
-
Neut - Quality tested
- Recommended Usage
-
Each lot of this antibody is quality control tested by neutralizing the production of human MCP-1/CCL2 induced by recombinant human IFN-α2 at 1 ng/mL in U937 cells. ND50 range: 4.5 - 30 ng/mL. It is recommended that the reagent be titrated for optimal performance for each application.
- RRID
-
AB_3662319 (BioLegend Cat. No. 638253)
AB_3662319 (BioLegend Cat. No. 638254)
Antigen Details
- Distribution
-
IFN-α is ubiquitously expressed.
- Function
- IFN-α stimulates cytotoxic T lymphocytes and natural killer cell function. IFN-α has immunomodulatory and antiviral properties. IFNα2a induces CXCL10 in human microvascular endothelial cells and pulmonary artery smooth muscle cells. It is induced by viral infection.
- Interaction
- Varieties of cells express the IFNα receptor (IFNAR).
- Ligand/Receptor
- IFNAR complex has two components, IFNAR1 and IFNAR2.
- Biology Area
- Immunology, Innate Immunity
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
- Bose A & Baral R. 2007. Immunol Lett. 108:68-77.
- Zhao W, et al. 2008. J Immunol. 180:5483-9.
- Badiger R, et al. 2012. PLoS One. 7:e46779.
- Aghemo A, et al. 2010. Nat Rev Gastroenterol Hepatol. 7:485-94.
- Becker-Merok A, et al. 2013. Lupus. 22:155-63.
- Mukherjee KK, et al. 2012. Indian J Med Res. 136:54-9.
- Gene ID
- 3440 View all products for this Gene ID
- UniProt
- View information about IFN-alpha2 on UniProt.org
Related Pages & Pathways
Pages
Related FAQs
- Do you guarantee that your antibodies are totally pathogen free?
-
BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
- Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
-
No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
- Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
-
No, BioLegend does not test for pathogens in-house unless otherwise indicated. However, we can recommend an outside vendor to perform this testing as needed.
- Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
-
We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.
Other Formats
View All IFN-α2 Reagents Request Custom ConjugationDescription | Clone | Applications |
---|---|---|
Ultra-LEAF™ Purified anti-human IFN-α2 | W20057A | Neut |
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
-
Ultra-LEAF™ Purified anti-human IFN-α2
Recombinant human IFN-α2 (Cat. No. 592702) (black circles) i...
Follow Us